Compass Therapeutics Stock Performance
| CMPX Stock | USD 2.09 0.01 0.48% |
The firm shows a Beta (market volatility) of 1.43, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Compass Therapeutics will likely underperform. At this point, Compass Therapeutics has a negative expected return of -0.43%. Please make sure to confirm Compass Therapeutics' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Compass Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Compass Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (0.48) | Five Day Return 1.46 | Year To Date Return 49.29 | Ten Year Return (75.41) | All Time Return (75.41) |
1 | Acquisition by Gray Mary Ann of 45000 shares of Compass Therapeutics subject to Rule 16b-3 | 02/28/2025 |
2 | Acquisition by Schuetz Thomas J. of 30000 shares of Compass Therapeutics at 2.83 subject to Rule 16b-3 | 03/11/2025 |
3 | Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 23 Study Evaluating Tovecimig in Patients with Biliar... | 03/31/2025 |
4 | Compass Therapeutics Rating Increased to Outperform at Leerink Partners | 04/03/2025 |
5 | Compass Therapeutics Price Target Raised to 24.00 | 04/07/2025 |
6 | Disposition of 3571428 shares by Orbimed Advisors Llc of Compass Therapeutics at 1.59 subject to Rule 16b-3 | 04/09/2025 |
7 | Major Stock Sell-Off at Compass Therapeutics by Key Directors - TipRanks | 04/11/2025 |
8 | Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Can... | 04/21/2025 |
9 | Insider Trading | 04/28/2025 |
10 | H.C. Wainwright maintains Compass stock Buy rating, 24 target - Investing.com | 04/29/2025 |
11 | Compass Therapeutics to Participate in Upcoming May Investor Events | 05/06/2025 |
12 | Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update | 05/08/2025 |
13 | Guggenheim Adjusts Price Target for Compass Therapeutics CMPX Stock News | 05/09/2025 |
| Begin Period Cash Flow | 24.2 M |
Compass Therapeutics Relative Risk vs. Return Landscape
If you would invest 311.00 in Compass Therapeutics on February 24, 2025 and sell it today you would lose (102.00) from holding Compass Therapeutics or give up 32.8% of portfolio value over 90 days. Compass Therapeutics is currently does not generate positive expected returns and assumes 5.9109% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Compass, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Compass Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compass Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Compass Therapeutics, and traders can use it to determine the average amount a Compass Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0729
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CMPX |
Estimated Market Risk
| 5.91 actual daily | 52 52% of assets are less volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Compass Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Compass Therapeutics by adding Compass Therapeutics to a well-diversified portfolio.
Compass Therapeutics Fundamentals Growth
Compass Stock prices reflect investors' perceptions of the future prospects and financial health of Compass Therapeutics, and Compass Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Compass Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (72.73) % | ||||
| Current Valuation | 182.76 M | ||||
| Shares Outstanding | 138.28 M | ||||
| Price To Book | 2.62 X | ||||
| Price To Sales | 340.01 X | ||||
| Revenue | 850 K | ||||
| Gross Profit | 850 K | ||||
| EBITDA | (61.25 M) | ||||
| Net Income | (49.38 M) | ||||
| Cash And Equivalents | 132.02 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 15.17 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.36 X | ||||
| Book Value Per Share | 0.80 X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Earnings Per Share | (0.40) X | ||||
| Market Capitalization | 289.01 M | ||||
| Total Asset | 140.4 M | ||||
| Retained Earnings | (364.68 M) | ||||
| Working Capital | 123.88 M | ||||
About Compass Therapeutics Performance
Evaluating Compass Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Compass Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Compass Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.33) | (0.35) |
Things to note about Compass Therapeutics performance evaluation
Checking the ongoing alerts about Compass Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Compass Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Compass Therapeutics generated a negative expected return over the last 90 days | |
| Compass Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 850 K. Net Loss for the year was (49.38 M) with profit before overhead, payroll, taxes, and interest of 850 K. | |
| Compass Therapeutics currently holds about 132.02 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Compass Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Guggenheim Adjusts Price Target for Compass Therapeutics CMPX Stock News |
- Analyzing Compass Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Compass Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Compass Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Compass Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Compass Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Compass Therapeutics' stock. These opinions can provide insight into Compass Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.